Thursday, December 09, 2021

NEWS

Cuban vaccine Soberana 02 control group receives vaccination

Cuban vaccine Soberana 02 control group receives vaccination

Havana, Jun 7 (Prensa Latina) Members of the control group (placebo) of the Phase III clinical trial of Soberana 02 Covid-19 vaccine candidate receive immunization as of Monday, as part of that study starting in March in eight Havana municipalities.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The third stage of the research with Soberana 02, developed by the Finlay Institute of Vaccines (IFV) in Havana, is designed in periods of zero, 28 and 56 days with 44,010 sample of volunteers, divided into three groups.

The first group receives two doses of Soberana 02, the second group gets two doses plus a third immune booster with Soberana Plus and the third receives a placebo, a compound devoid of the active substances. IFV researchers confirmed the safety and immunogenicity of the vaccine candidate and at this stage, they are assessing the efficacy of the formulation in the symptomatic and severe disease, as well as in contagion and transmission.

Havana, the capital, is the epicenter of the disease, hence, along with the clinical trial, health authorities and the scientific community decided to extend vaccination to risk groups and territories at first with Abdala (CIGB-66), the second anti-Covid-19 vaccine candidate that is also being tested as a future vaccine.

To date, more than 2,700,000 people have received at least one dose of the vaccine candidates in intervention studies and health interventions.

ef/iff/jf/alb

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.